Scarica l'app Stockscreener
7.00
0.99%
-0.07
Dopo l'orario di chiusura:
7.00
Precedente Chiudi:
$7.07
Aprire:
$6.84
Volume 24 ore:
919.73K
Relative Volume:
0.33
Capitalizzazione di mercato:
$413.76M
Reddito:
$216.11M
Utile/perdita netta:
$-220.47M
Rapporto P/E:
-1.8735
EPS:
-3.7363
Flusso di cassa netto:
$-110.44M
1 W Prestazione:
-1.69%
1M Prestazione:
-14.32%
6M Prestazione:
+35.66%
1 anno Prestazione:
+55.21%
Intervallo 1D:
$6.76
$7.00
Intervallo di 1 settimana:
$6.57
$7.25
Portata 52W:
$3.8092
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Nome
Vanda Pharmaceuticals Inc
Settore
Industria
Telefono
202-734-3400
Indirizzo
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
7.00 | 413.76M | 216.11M | -220.47M | -110.44M | -3.7363 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-05 | Iniziato | Truist | Buy |
| 2025-11-05 | Iniziato | B. Riley Securities | Buy |
| 2024-10-31 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Downgrade | Jefferies | Buy → Hold |
| 2021-05-12 | Iniziato | BofA Securities | Buy |
| 2021-01-14 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-03-16 | Downgrade | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-07 | Downgrade | Citigroup | Buy → Neutral |
| 2019-08-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-07-25 | Downgrade | Stifel | Buy → Hold |
| 2018-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Reiterato | Jefferies | Buy |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-09-21 | Ripresa | Oppenheimer | Outperform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2017-09-14 | Reiterato | Piper Jaffray | Overweight |
| 2017-06-27 | Ripresa | Piper Jaffray | Overweight |
| 2017-05-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-04-12 | Iniziato | Oppenheimer | Outperform |
| 2016-11-09 | Iniziato | Aegis Capital | Buy |
| 2016-10-06 | Ripresa | Jefferies | Buy |
Mostra tutto
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
Rate Cut: Is Vanda Pharmaceuticals Inc affected by consumer sentimentStop Loss & Consistent Income Trade Recommendations - baoquankhu1.vn
Downgrade Watch: Can Vanda Pharmaceuticals Inc ride the EV waveDip Buying & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Vanda Pharmaceuticals executive Timothy Williams to resign as general counsel - Investing.com Australia
Vanda Announces Resignation of Senior Legal Executive - TipRanks
Timothy Williams resigns as Senior Vice President, General Counsel and Secretary at Vanda - TradingView
Vanda Pharmaceuticals (NASDAQ: VNDA) general counsel resigns role - Stock Titan
Vanda Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
VNDA Technical Analysis & Stock Price Forecast - Intellectia AI
Aug Levels: Can Vanda Pharmaceuticals Inc ride the EV wavePortfolio Return Report & Low Risk Investment Opportunities - baoquankhu1.vn
Pullback Watch: Will Vanda Pharmaceuticals Inc outperform tech stocksRate Cut & Reliable Momentum Entry Alerts - baoquankhu1.vn
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Update - MarketBeat
Vanguard disaggregates holdings; reports 0 shares of Vanda Pharmaceuticals (VNDA) - Stock Titan
Truist reiterates Vanda Pharmaceuticals stock rating after EMA decision By Investing.com - Investing.com Canada
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above 200-Day Moving AverageHere's Why - MarketBeat
Vanda Pharmaceuticals stock faces institutional dominance amid biotech sector volatility and retail - AD HOC NEWS
Gastroparesis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma - Barchart
Gastroparesis Pipeline 2026: FDA Updates, Therapy - openPR.com
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) added to S&P Biotechnology Select Industry Index - MarketScreener
Vanda Pharmaceuticals Faces New Market Challenges Amid Share Sale and Regulatory Roadblocks - timothysykes.com
If You Invested $1,000 in Vanda Pharma (VNDA) - Stock Titan
Insider Sell: Can Vanda Pharmaceuticals Inc ride the EV wave2026 PostEarnings & Intraday High Probability Setup Alerts - baoquankhu1.vn
CEO’s Significant Stock Sale Raises Concerns for Vanda Pharmaceuticals - timothysykes.com
Vanda Pharmaceuticals Faces Shareholder Movements and Regulatory Setbacks - StocksToTrade
Vanda Pharmaceuticals Inc. (VNDA) latest stock news and headlines - Yahoo Finance Singapore
Vanda stock draws heavy buzz ahead of FDA verdict on Bysanti for bipolar, schizophrenia - MSN
Vanda Pharmaceuticals Raises Concerns Over FDA's New Guidance on Drug Development - Intellectia AI
VNDA Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
What's going on with Vanda Pharma stock Tuesday? - MSN
Vanda Pharmaceuticals Faces Setbacks as CEO Mihael Polymeropoulos Sells Shares - StocksToTrade
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerat - GuruFocus
Vanda Pharmaceuticals urges FDA to accelerate move away from animal testing - Traders Union
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods - Bitget
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods – Company AnnouncementFT.com - Financial Times
Hedge Fund Moves: Is Vanda Pharmaceuticals Inc a strong candidate for buy and holdSwing Trade & Low Risk Entry Point Guides - baoquankhu1.vn
Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Gap UpTime to Buy? - MarketBeat
Growth Report: Will Vanda Pharmaceuticals Inc outperform tech stocks2026 Decliners & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Vanda Pharmaceuticals Stock (ISIN: US92178N1054) Faces Heightened Scrutiny Amid Pipeline Setbacks an - AD HOC NEWS
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Growth in Short Interest - MarketBeat
CEO Moves: Why is Vanda Pharmaceuticals Inc stock going up2026 Market Overview & Precise Swing Trade Alerts - baoquankhu1.vn
Why did Vanda Pharmaceuticals stock slide 7% pre-market today? - MSN
Why Vanda Pharmaceuticals (VNDA) Is Up 17.4% After Rare FDA Hearing Granted On HETLIOZ Jet Lag - Yahoo Finance
DC Circ. Spends Hours Debating 'Same' Generic Label Reqs - Law360
Vanda Pharmaceuticals Hits New 52-Week High of $9.94, Surges 59.87% - Markets Mojo
Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline - Investing.com Nigeria
Vanda Pharmaceuticals (VNDA) Is Up 13.3% After Rare FDA Hearing Granted on HETLIOZ Jet Lag Bid - simplywall.st
Vanda Advances NEREUS Launch With Direct-to-Consumer Strategy - The Globe and Mail
Vanda Pharmaceuticals at The Citizens Life Sciences Conference: Strategic Growth Insights - Investing.com Canada
VNDA: BYSANTI and Nereus launches drive growth, with key pipeline milestones expected by year-end - TradingView
Vanda Pharmaceuticals (VNDA) price target increased by 15.96% to 13.90 - MSN
Vanda Pharmaceuticals (NASDAQ: VNDA) CEO outlines DTC channel for FDA-approved motion drug - Stock Titan
Vanda Pharmaceuticals Inc Azioni (VNDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):